27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Prior work suggests that perceived value may shape online support use, yet practical and trust-related barriers may still impede uptake even when beliefs are favorable. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In female participants, higher education was associated with lower Thal amyloid phase, diffuse plaques, neuritic plaques, and Braak stage ({beta} range, -0.097 to -0.071; qFDR<.026); none was significant among male participants. 5 key findings →
Design: cohort study Participants: 2,592 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BACKGROUNDSubjective cognitive decline (SCD) may precede mild cognitive impairment (MCI), but not all individuals with SCD progress to MCI. 5 key findings →
Design: longitudinal study Participants: 1,352 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Spatial omics enables the integration of high-dimensional molecular organization with clinical outcomes, yet incorporating spatial single-cell information into predictive models at the population scale remains challenging. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Brain iron accumulation is well established in Alzheimers disease (AD), but whether the two share a genetic basis remains unclear. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundAlzheimers disease (AD) pathology often accumulates years before memory loss, creating a need to identify high-risk individuals presymptomatically. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sex differences in Alzheimers disease (AD) genetic effects and regulatory contexts remain incompletely resolved. 3 key findings →
Participants: 449,335 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Monoamine oxidase B (MAO-B) is a high-density protein located mainly in astrocytes that influences mitochondrial function and transition to astrogliosis. 2 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundDementia is rising worldwide, and in Alzheimer Disease (AD) the loss of communication adds to the burden. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundDeep-learning models predict mild cognitive impairment (MCI)-to-Alzheimers disease (AD) conversion from structural MRI with high accuracy. 1 key finding →
Design: longitudinal study Participants: 40 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
ResultsThe CNR2 missense variant rs4649124 was associated with increased vascular dementia risk (BH-adjusted P = 0.049) after correction at the 5% false discovery rate (FDR) threshold, with additional associations at the 10% FDR threshold for all-cause dementia risk (BH-adjusted P = 0.051) and lower circulating APP (BH-adjusted P = 0.088) and BDNF (BH-adjusted P = 0.083) levels. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Greater baseline WMH burden was associated with differential longitudinal progression in converters across eleven clinical outcomes, including cognition, gait, and functional independence (all q<0.05). 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
ObjectiveTo determine whether a multi-trait polygenic profile for dementia is associated with dementia- and disability-free survival in middle-aged and older adults. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundAnti-amyloid-{beta} (A{beta}) monoclonal antibodies are disease-modifying treatments for early Alzheimers disease but are associated with amyloid-related imaging abnormalities (ARIA) and intracranial hemorrhage (ICH). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
INTRODUCTIONIndividuals with Alzheimers disease (AD) exhibit substantial heterogeneity in the severity of vascular changes and neurodegeneration, making the identification of biologically meaningful subtypes across the AD spectrum critical for improving prognosis and tailoring interventions. 1 key finding →
Design: longitudinal study Participants: 1,396 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Large language models (LLMs) are increasingly used for qualitative analysis, but strong language performance does not guarantee strong interpretation when meaning depends on method and context. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundTuberous sclerosis complex (TSC) is a rare autosomal dominant neurodevelopmental disorder caused by loss-of-function mutations in TSC1 or TSC2, resulting in chronic hyperactivation of the mechanistic target of rapamycin (mTOR) pathway. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings show that model-based, adaptive assessments can support high-frequency, remote detection and scalable longitudinal monitoring of early memory decline, providing a new way to assess memory decline trajectories in healthy aging and dementia. 3 key findings →
Design: longitudinal study Participants: 24 Evidence: moderate
Full summary, score breakdown and related studies → Original source
BackgroundThe 10 Year Health Plan for England indicates governmental intention to shift care from hospital to community. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundClonal haematopoiesis (CH), the age-related expansion of mutated blood stem cells, is detectable in around 10% of people in their seventies, rises steeply with age, and is associated with several diseases. 5 key findings →
Design: longitudinal study Participants: 1,091 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundNon-pharmacological interventions may enhance motor-cognitive integration in prodromal Alzheimers disease (pAD). 5 key findings →
Design: randomized controlled trial Participants: 68 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Higher education (OR = 1.23, SE = 0.05, 95% CI = [1.10, 1.36], p < 0.001), female sex (OR = 1.30, SE = 0.09, 95% CI = [1.10, 1.55], p = 0.003), and lower age (OR = 0.67, SE = 0.04, 95% CI = [0.61, 0.73], p < 0.001) were associated with increased odds of SuperAger status. 5 key findings →
Participants: 3,513 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Gross brain findings help guide differential diagnosis, but their diagnostic value across major neurodegenerative diseases remains incompletely characterized. 5 key findings →
Participants: 5,613 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ObjectivesSubjective word-finding complaints (SWFC) are among the most frequent cognitive complaints in cognitively unimpaired older adults (CU). 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Plasma biomarkers of amyloid-associated tau phosphorylation (T1) and established tau proteinopathy (T2) can approximate Alzheimers disease stage, but whether plasma-defined stages correspond to broader biological states is unknown. 1 key finding →
Design: cross-sectional Participants: 1,035 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →